Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

@article{Anker2003PrognosticIO,
  title={Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study},
  author={S. Anker and A. Negassa and A. Coats and Rizwan Afzal and P. Poole‐Wilson and J. Cohn and S. Yusuf},
  journal={The Lancet},
  year={2003},
  volume={361},
  pages={1077-1083}
}
BACKGROUND Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. METHODS We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial… Expand
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
TLDR
Weight loss and leanness are important predictors of poor prognosis in CHF and the detection of weight change, and particularly weight loss, should be considered as an adverse sign prompting further evaluation. Expand
Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction
TLDR
Among patients with HFpEF, weight loss was independently associated with higher risk of all-cause mortality, and weight gain was not associated with better survival. Expand
Effects of Weight Loss in Outpatients With Mild Chronic Heart Failure: Findings From the J-MELODIC Study.
TLDR
In patients with mild CHF, ≥5% weight loss was a significant predictor for subsequent cardiovascular death or hospitalization for HF and underweight was not associated with these outcomes. Expand
Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure.
TLDR
Patients with CHF due to LVSD who receive beta- blocker were less likely to develop cachexia and more likely to have significant weight gain and better outcome compared to patients who did not receive or tolerate beta-blocker. Expand
Prediction of all-cause and cardiovascular mortality with weight loss in patients with chronic heart failure: a meta-analysis
TLDR
This meta-analysis suggests that weight loss is independently associated with an increased risk of all-cause mortality in patients with CHF and suggested that weight Loss may be a strong and independent predictor of poor health. Expand
Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program
TLDR
In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema). Expand
Perils of weight loss: the advantage of being obese in patients with heart failure
TLDR
The paper under evaluation clarifies and offers further insight into the impact of BMI and weight loss on prognosis in a large sample of heart failure patients and raises many questions regarding the underlying pathophysiology that leads to this counterintuitive relationship observed in the obese heart failure group. Expand
Beta-blockers and weight change in patients with chronic heart failure.
TLDR
Beta-blocker use and intensification of heart failure treatment is associated with weight gain in CHF, and the increase is greater in those who are nonedematous and tends to occur in patients with NYHA functional class I and II symptoms. Expand
Weight Loss in Obese Patients With Heart Failure
TLDR
Weight loss ≥5% in patients with chronic HF was associated with high long‐term mortality, particularly among obese patients with HF. Expand
PREDICTORS OF WEIGHT LOSS IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUSED LEFT VENTRICULAR EJECTION FRACTION
TLDR
Predictors of body weight (BW) loss in patients with CHF and a reduced left ventricular ejection fraction are age, CRP level, III-IV NYHA class, lower cholesterol levels, as well as lower rates of flow-dependent vasodilator response and hip circumference. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
TLDR
Whether losartan is superior to captopril in improving survival and is better tolerated and the ELITE II Losartan Heart Failure Survival Study is confirmed. Expand
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity.
TLDR
In patients with chronic heart failure, increasing BMI is not an adverse prognostic feature and Thinner patients appear to have a poorer prognosis. Expand
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.
TLDR
There is a pronounced but variable neurohormonal activation in heart failure even in patients with similar clinical findings, and the effect of enalapril on mortality is related to hormonal activation in general and the renin-angiotensin system in particular. Expand
Wasting as independent risk factor for mortality in chronic heart failure
TLDR
The cachectic state was predictive of 18-month mortality independent of age, NYHA class, left-ventricular ejection fraction, and peak oxygen consumption, and a subset of patients at extremely high risk of death was identified. Expand
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
TLDR
The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions. Expand
Effect of carvedilol on survival in severe chronic heart failure.
TLDR
The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial. Expand
Effect of carvedilol on survival in severe chronic heart failure.
TLDR
The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial. Expand
Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight.
TLDR
Ventricular assist device implantation results in a short-term fall in tumour necrosis factor alpha and interleukin-6, but no change in CD14 or tumour Necrosis factor receptor, suggesting that the pathophysiological process resulting in inflammation was not altered by left ventricular assist devices implantation. Expand
The relationship between obesity and mortality in patients with heart failure.
TLDR
In a large cohort of patients with advanced HF of multiple etiologies, obesity is not associated with increased mortality and may confer a more favorable prognosis, and weight loss promotion in medically optimized patients with HF is a worthwhile therapeutic goal. Expand
Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure
TLDR
Assessment of sT NF-R1 may be useful in identifying patients who are at high risk of death and in monitoring patients undergoing anti-TNF-alpha treatment, independent of established markers of CHF severity. Expand
...
1
2
3
...